All In Biotech

Drug Trial Radar · NCT06030375

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567. A Single-centre, Placebo-controlled, Randomised, Double-blind Study in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Feb 17, 2020

Primary completion

Apr 27, 2020

Study completion Apr 27, 2020

Sponsor

Lead sponsor
Novakand Pharma ABIndustry
Sponsor type
Industry
First posted
Sep 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study was planned to consist of 24 healthy subjects in 3 dosing cohorts receiving a continuous i.v. infusion of KAND567 or placebo for 6 h (6 subjects on active and 2 subjects on placebo per cohort), with the option of two additional cohorts of the same size and group composition.

Conditions

  • Healthy

Interventions

  • KAND567Drug

    Continuous intravenous infusion for 6 hours

  • PlaceboOther

    Continuous intravenous infusion for 6 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability after continuous infusion of KAND567, as measured by adverse events (AEs)Time frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
  2. Safety and tolerability after continuous infusion of KAND567, as measured by vital signsTime frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
  3. Safety and tolerability after continuous infusion of KAND567, as measured by ECGTime frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
  4. Safety and tolerability after continuous infusion of KAND567, as measured by lab safety testsTime frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
  5. Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by CssTime frame: From the first IMP administration (Day 1) until Day 2
  6. Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by AUCTime frame: From the first IMP administration (Day 1) until Day 2
  7. Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by t1/2zTime frame: From the first IMP administration (Day 1) until Day 2
  8. Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by VssTime frame: From the first IMP administration (Day 1) until Day 2
  9. Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by CLTime frame: From the first IMP administration (Day 1) until Day 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Services Turku (CRST)

    Turku, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.